JewishStatusOpen the app

Kol Haolam · Oct 29, 2026

Kol Haolam — photo status

Eli Lilly announced that its experimental obesity and diabetes drug, retatrutide, significantly outperformed Ozempic in a clinical trial, with patients losing an average of 44–47 pounds over about 18 months, compared with 21 pounds for those taking Ozempic.

Eli Lilly announced that its experimental obesity and diabetes drug, retatrutide, significantly outperformed Ozempic in a clinical trial, with patients losing an average of 44–47 pounds over about 18 months, compared with 21 pounds for those taking Ozempic.

Watch in the app All of Kol Haolam's statuses

More from Kol Haolam